Startup profile · funding coverage
Dyno Therapeutics funding, valuation and investors
AI-designed AAV capsids for gene therapy — CapsidMap platform with Novartis, Sarepta, Roche.
Keep track of Dyno Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$100M · May 2021
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$100M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Cambridge, Massachusetts
Overview
Dyno Therapeutics designs AI-optimized AAV viral vectors for gene therapy delivery — its CapsidMap platform partners with Novartis, Sarepta, and Roche on capsid engineering. Raised $100M Series A in May 2021 led by a16z with Lux Capital and CRV participating. Spinout from George Church's Harvard lab applying machine learning to viral vector design.
Why Dyno Therapeutics is interesting
a16z-led $100M Series A with Lux and CRV — gene-delivery bottleneck play as pharma outsources capsid engineering.
Product & use cases
CapsidMap AI platform designs optimized AAV capsids for targeted gene therapy delivery — partnering with pharma on custom vectors.
- Custom AAV capsid design for pharma gene therapy programs
- Improving tissue targeting and reducing immunogenicity
- Accelerating preclinical vector selection via ML
Key facts
- Series A (May 2021): $100M led by a16z; Lux, CRV (Dyno press)
- Partnerships with Novartis, Sarepta, Roche
- Spinout from George Church Harvard lab
Funding history (newest first)
Series A
2021-05 $100MSource: https://www.dynotx.com/news/dyno-raises-100m-series-a
Investors in our directory
Funds linked from Dyno Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: AI + wet-lab iteration loop from Harvard Church lab origins — deep capsid engineering expertise.
Gene therapy delivery is a bottleneck — better capsids mean safer, more effective treatments. Dyno sells platform partnerships vs. owning therapeutic pipeline.
-
Vigene Biosciences adjacent
AAV manufacturing; less AI design focus.
-
Oxford Biomedica adjacent
Lentiviral and AAV manufacturing partner.
-
In-house pharma labs incumbent
Big pharma internal vector engineering.
-
4D Molecular Therapeutics adjacent
Targeted AAV vectors; public biotech.
Notable stories
- Dyno spun out of George Church's lab applying ML to AAV capsid evolution — a16z led $100M Series A as pharma sought delivery solutions (Dyno press, 2021).
Industries
Related funding articles
Venture Capital Tracker pieces that cover Dyno Therapeutics's financing or category context.
FAQs about Dyno Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.